NEW YORK (Reuters Health) – Results of a Mexican study indicate that 2 months of treatment with the antiinflammatory agent diacerein increases insulin secretion and improves A1C levels…
NEW YORK (Reuters Health) – For patients with acute MI given early unfractionated heparin, a switch to bivalirudin before undergoing primary percutaneous coronary intervention results in improved cardiac…
NEW YORK (Reuters Health) – After chemotherapy-induced remission of follicular lymphoma, vaccination with a patient-specific tumor-derived antigen improves disease-free survival, a multicenter team has shown. Furthermore, the vaccine…
NEW YORK (Reuters Health) – Growth hormone treatment of adults isn’t associated with an increased risk of developing diabetes, according to a new report. “The strength of the…
NEW YORK (Reuters Health) – After catheter ablation, patients with obstructive sleep apnea (OSA) are more likely to experience recurrence of atrial fibrillation (AF) than are their OSA-free…
NEW YORK (Reuters Health) – Diabetes incidence falls during rosiglitazone treatment but returns to baseline after rosiglitazone withdrawal, according to the preprint version of a study that is…
NEW YORK (Reuters Health) – Patients with type 2 diabetes without retinopathy can be safely screened for sight-threatening vision problems every 3 years instead of every 1 or…
NEW YORK (Reuters Health) – Very small breast tumors that generate extensive lymph node involvement may be more biologically aggressive than larger tumors with the same degree of…
NEW YORK (Reuters Health) – For patients with idiopathic sudden sensorineural hearing loss, intratympanic injection of corticosteroids is no better or worse than oral corticosteroid therapy, but is…
NEW YORK (Reuters Health) – Results of a meta-analysis confirm that the oral tyrosine kinase inhibitor gefitinib is effective as first-line therapy in patients with advanced non-small-cell lung…
